Open AccessIs there a place for the combination of brentuximab vedotin and bendamustine in treatment of patients with relapsed/refractory Hodgkin lymphoma?
Author(s) -
Robert W. Chen
Publication year - 2018
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2018.05.40
Subject(s) - brentuximab vedotin , bendamustine , medicine , refractory (planetary science) , oncology , lymphoma , hodgkin lymphoma , rituximab , biology , astrobiology